价格谈判成功药品临床使用分析

Analysis of Clinical Use of Successfully Price Negotiated Drugs

目的探讨药品价格谈判制度在保证临床疗效的前提下减轻患者经济负担的效果。方法比较首批谈判成功药品进入医保前后在医院的价格、用量及销售金额,比较第二批谈判成功药品进入医保前后的价格、用量变化情况,并与谈判成功价比较。结果首批谈判成功的3种药品单价均下降50%以上,用量平均增加2. 7倍,销售金额平均增加42%;第二批谈判成功的36种药品中,有19种在医院使用,用量不多,销售金额也仅占总销售金额的2. 24%～2. 42%;谈判成功药品进入医保后,患者花费大幅降低,以曲妥珠单抗(赫赛汀)为例,普通非医保、贫困医保及普通医保的花费分别只有原来的1/3,1/4,1/10。结论药品价格谈判制度有效降低了优质药品的价格,进入医保目录后,患者负担进一步减轻,更容易坚持治疗,从而保证了药效,进而可促进我国医药事业的良性发展。

Objective To investigate the effect of drug price negotiation system on reducing economic burden of patients under the premise of ensuring clinical efficacy. Methods The price,dosage and sales amount of the first batch of successfully price negotiated drugs in the hospital were compared before and after the entry into the health insurance. The changes of price and dosage of the second batch of successfully price negotiated drugs in the hospital were compared before and after the entry into the health insurance,and the price change was compared with the successful negotiation price. Results The unit price of the three drugs successfully negotiated in the first batch decreased by more than 50%,the average dosage increased by 2. 7 times and the average sales amount increased by 42%. Of the 36 drugs successfully negotiated in the second batch,19 drugs were used in hospitals with little dosage,and the sales amount accounted for only 2. 24%-2. 42% of the total sales amount. After the negotiations were successful and the drugs entered into health insurance,the cost of the patients has been greatly reduced,taking trastuzumab（ Herceptin） as an example,the cost of patients with general non-health insurance,poor health insurance and general health insurance were only 1/3,1/4 and 1/10 of the original cost respectively. Conclusion Drug price negotiation system can effectively reduce the price of high-quality drugs. After entering the list of health insurance,the burden of patients is further reduced,and it is easier for patients to adhere to treatment,thus guaranteeing the curative effect and promoting the healthy development of China＇s pharmaceutical industry.